Observational studySurgical endoscopy2025
Patient-reported outcomes after lobectomy vs. segmentectomy for early-stage non-small cell lung cancer.
Observational study in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- [Effects ofNan fang yi ke da xue xue bao = Journal of Southern Medical UniversityTrial
- Effects of pulmonary rehabilitation in people with lung cancer after lung resection: a systematic review and meta-analysis.Journal of cancer survivorship : research and practice · 2026Review
- Thoracoscopic segmentectomy versus lobectomy for early-stage non-small cell lung cancer: efficacy, postoperative recovery, and prognosis.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSurgical resection is the cornerstone for early-stage non-small cell lung cancer (NSCLC), with lobectomy historically standard. Evolving techniques have spurred debate comparing lobectomy and segmentectomy. This study analyzed early postoperative patient-reported symptoms and functional status in patients with early NSCLC undergoing either procedure.
methodsThis observational cohort study included 248 patients (Lobectomy = 92, Segmentectomy = 156) with early-stage NSCLC (tumor diameter ≤ 2 cm) who underwent uniport video-assisted thoracoscopic surgery (VATS), from December 2021 to December 2023. Patient-reported outcomes were collected using the Perioperative Symptom Assessment for Patients Undergoing Lung Surgery scale at preoperative day 1, daily from postoperative days 1-4, and weekly for postoperative weeks 1-4. We compared early postoperative symptom/functional impairment scores, recovery time from moderate-to-severe symptoms, and short-term clinical outcomes.
resultsBoth groups exhibited comparable early postoperative symptoms and functional status. No significant differences were observed between the two groups in any of the 7 symptom items or the 2 function items (all P > 0.05). The time to recovery from moderate-to-severe symptoms and functional impairment was also similar between the groups. Furthermore, there were no statistically significant differences in short-term clinical outcomes, including operative time, postoperative hospital stays, drainage time, discharge scores, or complication rates (all P > 0.05).
conclusionFor early-stage NSCLC (tumor diameter ≤ 2 cm) undergoing uniport VATS, lobectomy and segmentectomy yield largely similar early postoperative symptom/functional burden, recovery times, and short-term outcomes. Considering external evidence on long-term oncology and function, segmentectomy is supported as a highly suitable option for this patient population.
Indexed as
Identifiers
40926159What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.